R1507 + bevacizumab + mFOLFOX6

**R1507 + bevacizumab + mFOLFOX6** is an investigational multi-agent combination regimen used in cancer clinical trials, particularly in advanced or metastatic colorectal cancer. - **R1507** is an investigational humanized monoclonal antibody targeting the insulin-like growth factor 1 receptor (IGF-1R), aiming to inhibit tumor growth by blocking IGF-1R signaling. - **Bevacizumab** is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), blocking angiogenesis and reducing blood supply to tumors. - **mFOLFOX6** is a modified version of the FOLFOX6 chemotherapy regimen, which consists of oxaliplatin (a platinum-based alkylating agent that crosslinks DNA), leucovorin (folinic acid to enhance fluorouracil activity), and 5-fluorouracil (a pyrimidine analog antimetabolite inhibiting thymidylate synthase and DNA synthesis)[1][2][3][4][5]. The combination is used intravenously and is under investigation for synergistic anti-tumor effects by simultaneously targeting cancer cell proliferation (RL507), tumor angiogenesis (bevacizumab), and directly damaging DNA and inhibiting nucleotide synthesis (mFOLFOX6) in colorectal and potentially other gastrointestinal cancers.

Other names

bevacizumabmodified FOLFOX6FOLFOX6 modFOLFOX-6 modFOLFOX 6 mod